¿ªÔÆÌåÓý

18 years - VISION and IVY Networks, September 2024-January 2025. 

MMWR: Morbidity and Mortality Weekly Report. 2025

Infant respiratory syncytial virus immunization coverage in the Vaccine Safety Datalink: 2023-2024. 

Pediatrics. 2025

Patterns in prescribing and dispensing of influenza antivirals among adults with influenza presenting to urgent care and emergency department settings, VISION Network, 2023-2024. 

Clinical Infectious Diseases. 2025

Vaccination during pregnancy in the Vaccine Safety Datalink, 2002-2022. 

Pediatric Infectious Disease Journal. 2025

18 years with immunocompromising conditions - VISION Network, September 2023-February 2024. 

MMWR: Morbidity and Mortality Weekly Report. 2024

COVID-19 vaccination in the first trimester and major structural birth defects among live births. 

JAMA pediatrics. 2024

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 

Clinical Infectious Diseases. 2024

Effectiveness of the original monovalent and bivalent COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters in pregnant persons who were not immunocompromised: VISION Network, June 2022-August 2023. 

Open forum infectious diseases. 2024

Impact of the COVID-19 pandemic on health care utilization in the Vaccine Safety Datalink: retrospective cohort study. 

JMIR public health and surveillance. 2024

Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States. 

Clinical Infectious Diseases. 2024

Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 

Journal of Infectious Diseases. 2024

Obstetric complications and birth outcomes after antenatal coronavirus disease 2019 (COVID-19) vaccination. 

Obstetrics and Gynecology. 2024

Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection. 

Nature communications. 2024

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 

Lancet (London, England). 2024

Safety of the seasonal influenza vaccine in 2 successive pregnancies. 

JAMA network open. 2024

Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 

Clinical Infectious Diseases. 2024

Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy. 

Vaccine. 2023

Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 

Pediatrics. 2023

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 

Vaccine. 2023

Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 

JAMA network open. 2023

Influenza vaccination among pregnant people before and during the coronavirus disease 2019 (COVID-19) pandemic. 

Obstetrics and Gynecology. 2023

Medically attended acute adverse events in pregnant people after coronavirus disease 2019 (COVID-19) booster vaccination. 

Obstetrics and Gynecology. 2023

Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 

Journal of Infectious Diseases. 2023

Relationships between social vulnerability and coronavirus disease 2019 vaccination coverage and vaccine effectiveness. 

Clinical Infectious Diseases. 2023

Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. 

Vaccine. 2023

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 

Journal of Infectious Diseases. 2023

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic. 

Vaccine. 2022

Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 

American Journal of Transplantation. 2022

Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 

JAMA network open. 2022

Evaluation of acute adverse events after Covid-19 vaccination during pregnancy. 

New England Journal of Medicine. 2022

Health care utilization in the 6 months following SARS-CoV-2 infection. 

JAMA network open. 2022

Kawasaki disease following the 13-valent pneumococcal conjugate vaccine and rotavirus vaccines. 

Pediatrics. 2022

Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth - eight integrated health care organizations, United States, December 15, 2020-July 22, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 

Vaccine. 2022

Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 

Pediatrics. 2022

Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero. 

Pediatrics. 2022

Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 

BMJ (Clinical research ed.). 2022

COVID-19 vaccination coverage among insured persons aged â‰�16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

COVID-19 vaccination coverage among pregnant women during pregnancy - eight integrated health care organizations, United States, December 14, 2020-May 8, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 

New England Journal of Medicine. 2021

Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Surveillance for adverse events after COVID-19 mRNA vaccination. 

JAMA. 2021

Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. 

Therapeutic advances in drug safety. 2021

Order of live and inactivated vaccines and risk of non-vaccine-targeted infections in US children 11-23 months of age. 

Pediatric Infectious Disease Journal. 2020

Risk for subdeltoid bursitis after influenza vaccination: a population-based cohort study. 

Annals of Internal Medicine. 2020

Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non-vaccine-targeted infections from 24 through 47 months of age. 

JAMA. 2018